Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROUS OXIDE, USP vs FORANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.
Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.
Anesthesia induction and maintenance,Procedural sedation and analgesia,Off-label: labor analgesia, treatment of severe pain in emergency settings
Induction and maintenance of general anesthesia,Sedation for mechanical ventilation in intensive care
Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.
Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.
Terminal elimination half-life is 2–6 minutes (context-sensitive); rapid washout due to low blood solubility and high pulmonary elimination.
Context-sensitive half-life: 2-5 minutes after short exposure; prolonged to 30-60 minutes after prolonged administration due to accumulation in fat and muscle. Terminal elimination half-life: 0.5-1 hour.
Nitrous oxide is metabolized minimally (approximately 0.004%) via intestinal bacterial reduction to free radicals and nitrogen. Pulmonary excretion unchanged accounts for >99% of elimination.
Primarily hepatic via CYP2E1; also undergoes glucuronidation and defluorination.
Primarily eliminated via lungs as unchanged gas (>99% exhaled); negligible renal (<1%) or biliary/fecal elimination.
Primarily exhaled unchanged via lungs (>95%); <5% metabolized in liver to fluoride ions and other metabolites, which are excreted renally.
<0.5% (minimally bound; essentially unbound in plasma).
~40% bound to plasma proteins (mainly albumin).
0.5–1.0 L/kg (rapid distribution to vessel-rich tissues; maintains rapid onset and offset).
Vd: 1.5-2.0 L/kg, reflecting distribution to highly perfused tissues (brain, heart, liver, kidneys) and subsequent redistribution to muscle and fat.
Inhalation: 100% (administered as gas; absorbed directly across alveolar membrane).
100% via inhalation.
No dose adjustment required; nitrous oxide is minimally excreted renally.
No adjustment required.
No dose adjustment required; metabolism is minimal.
Use with caution; reduce dose in severe hepatic impairment (Child-Pugh C).
Inhalation: 5-50% nitrous oxide in oxygen, titrated to effect; for anesthesia, up to 70%.
Induction: 1-4% inspired; Maintenance: 0.5-2% inspired.
Decrease concentration and titrate slowly due to increased sensitivity; monitor for hypotension and hypoxia.
Reduce inspired concentrations by 25-50% due to increased sensitivity.
Nitrous oxide may cause megaloblastic anemia and neurological complications with prolonged use (e.g., >24 hours) due to inactivation of vitamin B12 and folate deficiency. Monitor for signs of B12 deficiency.
None
Risk of hypoxia due to diffusion hypoxia upon discontinuation; oxygen supplementation required. May cause bone marrow suppression, B12 deficiency neuropathy, and impaired vitamin B12-dependent enzyme activity. Use caution in patients with pre-existing neurological disease, hematologic disorders, or vitamin B12/folate deficiency. Chronic exposure can lead to reproductive toxicity and occupational hazard.
Risk of malignant hyperthermia,Respiratory depression,Hypotension,Hepatotoxicity with repeated use or in susceptible patients,Nephrotoxicity due to fluoride ions
Absolute: Known hypersensitivity, severe hematologic abnormalities (e.g., megaloblastic anemia), active vitamin B12 deficiency, need for prolonged oxygen therapy (e.g., pneumothorax, bowel obstruction), air trapping conditions (e.g., middle ear surgery, sinus infection). Relative: Pregnancy (first trimester), neurological disease, folate deficiency.
Known hypersensitivity to isoflurane or other halogenated agents,Known or suspected genetic susceptibility to malignant hyperthermia
No specific food interactions. However, patients with vitamin B12 deficiency or those on methotrexate should ensure adequate B12 and folate intake; nitrous oxide can deplete B12 stores. Heavy meals before sedation may increase risk of aspiration and nausea.
No specific food interactions are documented for isoflurane. However, patients should follow standard preoperative fasting guidelines (e.g., NPO for 8 hours prior to elective surgery) to reduce aspiration risk during anesthesia.
Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data show no increased risk of major malformations with brief, low-dose exposure. Second/third trimesters: Use is generally considered safe for short durations; prolonged or repeated exposure may reduce uterine blood flow and cause fetal hypoxia. There is no evidence of increased congenital anomalies from routine use in dentistry or surgery.
FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters: known to cause dose-dependent maternal hypotension and uterine relaxation, which may reduce placental perfusion; use only if clearly needed.
Nitrous oxide is rapidly eliminated from plasma; low levels may pass into breast milk. No published M/P ratio. After a single dose, breastfeeding can be resumed once the mother is alert and has recovered from anesthesia. Limited data suggest no adverse effects on nursing infants. Caution with repeated or high doses.
Isoflurane is excreted into breast milk in minimal amounts; M/P ratio is approximately 0.85. After inhalational anesthesia, the concentration in milk is low and rapidly cleared. The American Academy of Pediatrics considers it compatible with breastfeeding. However, it is recommended to discard milk for 24 hours post-procedure due to sedation and potential metabolites.
No dose adjustments are typically required for short-term use. However, due to increased minute ventilation and decreased functional residual capacity in pregnancy, onset of action may be faster and depth of anesthesia may be greater. Consider using lower inspired concentrations (e.g., 30-50% N2O in O2) to avoid maternal hypoxia. Avoid prolonged exposure to reduce risk of fetal hypoxia and methemoglobinemia.
No specific dose adjustment is required for pregnancy, but due to increased volume of distribution and decreased protein binding, a slightly lower dose may achieve desired anesthetic depth. Maintenance of uterine perfusion pressure is critical; avoid hypotension. The minimum alveolar concentration (MAC) is decreased by approximately 25% in pregnancy.
Nitrous oxide has a rapid onset (30-60 seconds) and offset; monitor for diffusion hypoxia upon discontinuation by administering 100% oxygen for 3-5 minutes. Avoid in patients with pneumothorax, bowel obstruction, middle ear surgery, or intracranial air due to risk of expansion. Use with caution in patients with vitamin B12 deficiency or methylenetetrahydrofolate reductase (MTHFR) mutations due to inactivation of methionine synthase. Nitrous oxide is a potent analgesic but weak anesthetic; always combine with an amnestic agent (e.g., benzodiazepine) for procedural sedation. In pediatric patients, use 30-50% concentration; higher concentrations may cause vomiting or excitement. Check waste gas scavenging systems to prevent occupational exposure.
FORANE (isoflurane) is a potent inhalational anesthetic with rapid onset and offset due to low blood-gas solubility. It causes dose-dependent respiratory depression and hypotension via peripheral vasodilation. Monitor end-tidal CO2 and arterial blood pressure closely. Avoid in patients with known or suspected malignant hyperthermia susceptibility. Use a calibrated vaporizer to deliver precise concentrations (1-3% for induction, 0.5-2% for maintenance).
You may feel lightheaded, euphoric, or have tingling sensations; this is normal and will resolve quickly after stopping the gas.,You will receive oxygen after the procedure to prevent a sudden drop in oxygen levels.,Do not eat a heavy meal for 2-3 hours before sedation to reduce the risk of nausea or vomiting.,Inform your healthcare provider if you have a history of vitamin B12 deficiency, anemia, or lung problems (e.g., pneumothorax).,You should not drive, operate machinery, or make important decisions for 24 hours after sedation.
This medication is for hospital use only and will be administered by an anesthesia provider.,You may experience drowsiness, dizziness, or confusion after waking from anesthesia.,Do not drive or operate machinery for at least 24 hours after receiving this drug.,Inform your doctor if you have a personal or family history of malignant hyperthermia.,Report any muscle rigidity, fever, or dark urine to your healthcare provider immediately.
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"Nitrous oxide, an NMDA receptor antagonist and anesthetic gas, can enhance the central nervous system (CNS) depressant effects of difenoxin, an opioid antidiarrheal that acts on mu-opioid receptors. This combination increases the risk of profound sedation, respiratory depression, and coma, particularly in elderly or debilitated patients. Concurrent use may also exacerbate hypotension and bradycardia due to synergistic effects on the autonomic nervous system."
"Nitrous oxide (N2O) is an NMDA receptor antagonist and can inhibit the enzyme methionine synthase, leading to decreased methionine and increased homocysteine levels. Lamotrigine, a sodium channel blocker and glutamate release inhibitor, has proconvulsant effects at high doses and can lower the seizure threshold. The combination may increase the risk of seizures and neurotoxicity, particularly in patients with underlying epilepsy or rapid dose escalation of lamotrigine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROUS OXIDE, USP vs FORANE, answered by our medical review team.
NITROUS OXIDE, USP is a Inhalational Anesthetic that works by Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.. FORANE is a Inhalational Anesthetic that works by Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROUS OXIDE, USP and FORANE depend on the specific clinical indication. These are both Inhalational Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROUS OXIDE, USP is: Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.. The standard adult dose of FORANE is: Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROUS OXIDE, USP and FORANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROUS OXIDE, USP is classified as Category C. Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data sh. FORANE is classified as Category C. FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.